

UCSF

UC San Francisco Previously Published Works

Title

Structural insights into μ -opioid receptor activation.

Permalink

<https://escholarship.org/uc/item/8ks4p3q1>

Journal

Nature, 524(7565)

ISSN

0028-0836

Authors

Huang, Weijiao
Manglik, Aashish
Venkatakrishnan, AJ
et al.

Publication Date

2015-08-01

DOI

10.1038/nature14886

Peer reviewed



Published in final edited form as:

Nature. 2015 August 20; 524(7565): 315–321. doi:10.1038/nature14886.

Structural insights into μ -opioid receptor activation

Weijiao Huang^{1,*}, Aashish Manglik^{1,*}, A. J. Venkatakrishnan^{1,2,3}, Toon Laeremans^{4,5}, Evan N. Feinberg^{1,2,3}, Adrian L. Sanborn^{1,2,3}, Hideaki E. Kato¹, Kathryn E. Livingston⁶, Thor S. Thorsen¹, Ralf Kling⁷, Sébastien Granier⁸, Peter Gmeiner⁷, Stephen M. Husbands⁹, John R. Traynor⁶, William I. Weis^{1,10}, Jan Steyaert^{4,5}, Ron O. Dror^{1,2,3}, and Brian K. Kobilka¹

¹Department of Molecular and Cellular Physiology, Stanford University School of Medicine, 279 Campus Drive, Stanford, CA 94305 USA

²Department of Computer Science, Stanford University, 318 Campus Drive, Stanford CA 94305 USA

³Institute for Computational and Mathematical Engineering, Stanford University, 475 Via Ortega, Stanford CA 94305 USA

⁴Structural Biology Brussels, Vrije Universiteit Brussel, Pleinlaan 2, B-1050 Brussel, Belgium

⁵Structural Biology Research Center, VIB, Pleinlaan 2, B-1050 Brussel, Belgium

⁶Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109, USA

⁷Department of Chemistry and Pharmacy, Friedrich Alexander University, Schuhstrasse 19, 91052 Erlangen, Germany

⁸Institut de Génomique Fonctionnelle, CNRS UMR-5203 INSERM U1191, University of Montpellier, F-34000 Montpellier, France

⁹Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, United Kingdom

¹⁰Department of Structural Biology, Stanford University School of Medicine, 299 Campus Drive, Stanford, CA 94305 USA

Reprints and permission information is available at www.nature.com/reprints.

Corresponding authors: Correspondence to: A.M. (amanglik@stanford.edu) or B.K.K. (kobilka@stanford.edu).

*These authors contributed equally to this work.

Supplementary Information is linked to the online version of the paper at www.nature.com/nature.

Author Contributions: W.H. developed functional purification protocols, expressed and purified μ OR, characterized the effect of nanobodies and G_i on μ OR ligand affinity, identified Nb39 for crystallography of the μ OR-Nb complex, performed crystallization trials, data collection, structure determination and refinement. A.M. established the project with biochemistry of active μ OR, prepared samples for llama immunization, validated nanobody activity, performed crystallization trials, and identified initial crystals of the μ OR-BU72-Nb complex suitable for diffraction studies. A.J.V. analyzed the polar network. A.J.V., E.F., and A.S. performed and analyzed molecular dynamics simulations with supervision from R.O.D. T.L. identified μ OR-binding nanobodies with supervision from J.S. S.G. established the biochemistry for purification of agonist-bound μ OR and prepared samples for μ OR immunization. H.E.K. helped with data collection and processing. T.S.T. helped with the characterization of the amino-terminal region. R.K. and P.G. analyzed BU72 and assessed alternative ligand structures. S.M.H. synthesized BU72. K.E.L. and J.R.T. helped with selection of opioid ligands including BU72 and performed dissociation kinetics experiments. W.I.W. supervised structure refinement. A.M. and B.K.K. provided overall project supervision, and wrote the manuscript with W.H. and R.O.D.

Author Information: Coordinates and structure factors for the μ OR-BU72-Nb39 complex are deposited in the Protein Data Bank under accession code 5C1M. Readers are welcome to comment on the online version of this article at www.nature.com/nature.

Competing financial interests: A.M., T.L., J.S., and B.K.K. have filed a patent for active-state stabilizing nanobodies for opioid receptors.

Summary

Activation of the μ -opioid receptor (μ OR) is responsible for the efficacy of the most effective analgesics. To understand the structural basis for μ OR activation, we obtained a 2.1 Å X-ray crystal structure of the μ OR bound to the morphinan agonist BU72 and stabilized by a G protein-mimetic camelid-antibody fragment. The BU72-stabilized changes in the μ OR binding pocket are subtle and differ from those observed for agonist-bound structures of the β_2 adrenergic receptor (β_2 AR) and the M2 muscarinic receptor (M2R). Comparison with active β_2 AR reveals a common rearrangement in the packing of three conserved amino acids in the core of the μ OR, and molecular dynamics simulations illustrate how the ligand-binding pocket is conformationally linked to this conserved triad. Additionally, an extensive polar network between the ligand-binding pocket and the cytoplasmic domains appears to play a similar role in signal propagation for all three GPCRs.

Introduction

The most powerful analgesic and addictive properties of opiate alkaloids are mediated by the μ OR¹. As the receptor primarily responsible for the effects of opium, the μ OR is one of the oldest drug targets within the pharmacopeia². Opioid receptors are highly versatile signaling molecules. Activation of the μ OR results in signaling through the heterotrimeric G protein G_i , resulting in analgesia and sedation as well as euphoria and physical dependence³. The μ OR can also signal through arrestin, and this pathway has been attributed to adverse effects of opioid analgesics including tolerance, respiratory suppression, and constipation⁴⁻⁶.

The μ OR has been the subject of intense focus for drug-discovery efforts over the past century, with the identification of numerous ligands of varying efficacy. These drugs occupy a wide chemical spectrum, from small organic molecules to a variety of endogenous and synthetic peptides⁷. Structure-activity studies have revealed that subtle changes in ligand structure can convert an agonist into an antagonist⁷. These studies have yielded a general hypothesis for the information encoded within GPCR ligands where distinct pharmacophores within a drug are responsible for efficacy (message) or selectivity (address)⁸ (Fig. 1a). For the morphinan ligands, our previous structural examination of the inactive states of the μ OR and the δ OR revealed molecular insights into ligand selectivity^{9,10}. To understand the structural basis for μ OR activation, we obtained a structure of this receptor in the active state using a combination of a high-affinity agonist and a G protein-mimetic camelid antibody fragment. A comparison of this structure with the inactive-state structures of the μ OR⁹ and δ OR^{10,11}, as well as the inactive and active-state structures of the β_2 AR¹²⁻¹⁵, M2R^{16,17}, and rhodopsin^{18,19}, provide insights into shared mechanisms of GPCR activation.

Results

Nanobody stabilized structure of the μ OR

The active states of ligand-activated GPCRs are likely unstable, even when bound to full agonists²⁰⁻²³. However, the active conformation can be stabilized by interactions between a receptor and its cognate G protein. This stabilization is reflected in a higher affinity for

agonists when GPCRs are in complex with their cognate G protein²⁴. In the case of the μ OR, the affinity for the morphinan agonist BU72 is enhanced by 47 fold when coupled to the G protein G_i (Fig. 1b, c). Efforts to obtain a structure of activated μ OR in complex with G_i have thus far not been successful. As an alternative, we have previously utilized camelid single-domain antibody fragments, nanobodies, as G protein-mimetics to stabilize the active conformation of the β_2 AR and M2R for structural study^{12,13,17}. For the β_2 AR, the conformation of the receptor obtained in complex with the G_s mimetic nanobody 80 (Nb80) was nearly identical to that in the β_2 AR- G_s complex²⁵ (RMSD 0.61 Å).

To generate G protein-mimetic nanobodies for the μ OR, llamas were immunized with purified μ OR bound to the peptide agonist DMT¹-DALDA²⁶ and reconstituted into phospholipid vesicles¹². We examined the ability of selected nanobodies to stabilize the high-affinity state for μ OR agonists. Purified μ OR was reconstituted into high-density lipoprotein (HDL) particles and agonist competition assays were performed in the presence or absence of nanobodies (Fig. 1b). In presence of 5 μ M nanobody 39 (Nb39), the affinity of the potent morphinan agonist BU72²⁷ increases from 470 pM to 16 pM (Fig. 1b). BU72 has a dissociation half-life of 140 minutes in the presence of Nb39 (Extended Data Fig. 1b). Nb39 also enhances the affinity of μ OR agonists DAMGO and endomorphin-2, indicating that the effect is not limited to morphinan agonists (Extended Data Fig. 1a).

Crystals of the μ OR bound to BU72 and Nb39 were obtained in a monoolein lipidic mesophase²⁸ and a complete data set to 2.1 Å was obtained by merging diffraction data from four crystals (Extended Data Table 1). Nb39 binds to the intracellular surface of μ OR (Fig. 1d, Extended Data Fig. 2), and mediates the majority of packing interactions between lipidic layers and adjacent Nb39- μ OR complexes in the crystal lattice. There are no packing interactions involving the extracellular surface of the receptor (Extended Data Fig. 1c). We observe a limited parallel dimeric packing interaction between μ OR molecules involving the extracellular end of transmembrane helix 1 (TM1), TM2, the first extracellular loop (ECL1), and helix 8 with a buried surface area of 460 Å² (Fig. 1e). A similar interface between TM1, TM2, and helix 8 was also observed in the inactive structure of μ OR with a slightly larger buried surface area of 615 Å² (Fig. 1e). The inactive structure also identified a more extensive parallel dimer interaction involving TM5 and TM6 with a buried surface area 1460 Å² (Fig. 1f). This interaction involving TM5 and TM6 would not be compatible with the conformational changes we observe in the active state (Fig. 1f). It is important to note that the physiologic relevance of these interfaces remains unclear.

Structural differences in the extracellular surface between inactive and active μ OR are relatively small (Fig. 2a) with the exception of the proximal N-terminus, as discussed below. Conformational changes at the cytoplasmic surface of the μ OR observed upon activation are similar to those observed for the β_2 AR, M2R and rhodopsin, with large outward movement of TM6 and a smaller inward movement of TM5 and TM7 (Fig. 2a, Extended Data Fig. 3). The conserved E/DRY motif at the intracellular end of TM3 plays a role in maintaining GPCRs in the inactive state. In rhodopsin, an ionic interaction between R135^{3,50} and E247^{6,30} in TM6 stabilizes TM6 in an inactive conformation (superscript numbers follow the Ballesteros-Weinstein numbering method for GPCRs²⁹). While there is no acidic amino acid at the end of TM6 of μ OR that can form a similar salt bridge with R165^{3,50}, R165^{3,50}

can form a hydrogen bond with T279^{6,34} (Fig. 2b). In the active states of the μ OR and metarhodopsin II, R^{3,50} forms a hydrogen bond with Y^{5,58}, stabilizing the inward movement of TM5 (Fig. 2b). R^{3,50} and Y^{5,58} assume a similar orientation in the M2R and the β_2 AR-G_s complex; however, they are not close enough to form a hydrogen bond (Extended Data Fig. 3a).

Agonist binding pocket

The morphinan scaffold of BU72 binds to the activated μ OR in a similar orientation to that observed previously for the irreversible antagonist β -funaltrexamine (β -FNA) at the inactive μ OR (Fig. 3a, Extended Data Fig. 4). Figure 3b shows that the overall structural differences in the orthosteric binding pockets of active and inactive μ OR are relatively subtle. The majority of interactions between BU72 and active μ OR are hydrophobic or aromatic in nature, with the exception of two conserved polar interactions (Fig. 3c, Extended Data Fig. 4). As observed previously in the inactive structures of the μ OR, δ OR and κ OR³⁰, the phenolic hydroxyl of BU72 engages in a water-mediated interaction with H297^{6,52}. In the active state, this network is more extended, and involves Y148^{3,33} and the backbone carbonyl of K233^{5,39}. An ionic interaction between the morphinan tertiary amine and D147^{3,32} is seen in both the active μ OR bound to BU72 and in inactive μ OR bound to β -FNA (Fig. 3c).

We also observe an unexpected interaction between BU72 and the amino-terminus of the μ OR, which forms a lid over the ligand-binding pocket (Fig. 3d and Extended Data Fig. 5). In particular, the amino-terminal residue H54 is positioned 2.6 Å from secondary amine of BU72. It is of interest that binding of BU72, as well as other structurally unrelated peptide agonists like DAMGO and DMT¹-DALDA, lead to conformational changes in the truncated amino terminus that can be detected by nuclear magnetic resonance (NMR) spectroscopy (Sounier *et al.*, companion manuscript). While interactions between the amino-terminus and the transmembrane core may indeed be important for μ OR function³¹, the specific interaction observed here is unlikely to be physiologically relevant as H54 is not highly conserved and the H54A mutation does not alter the affinity of BU72 in μ OR with the full length amino-terminus (μ OR wild-type K_i = 21 pM and μ OR H54A K_i = 30 pM in HEK293 membranes). Additionally, using a bioluminescence resonance energy transfer assay³², we observe no significant difference in the EC₅₀ of G_i activation by BU72 between the wild-type receptor and the H54A mutant (EC₅₀ for wild-type of 79±17 pM and H54A mutant of 67±20 pM).

While the morphinan core of BU72 is unambiguously placed within the electron density, there are two unexplained features of the ligand. We observe a strong positive electron density ($F_o - F_c$ signal) between the H54 side chain and the BU72 amine (Extended Data Fig. 5c). Attempts to identify the source of this density, including mass spectrometry for an alternative ligand structure and the presence an anomalous signal for a coordinated metal were unsuccessful (Extended Data Fig. 4). Another unexpected finding is the near-planar geometry of the sp³ hybridized carbon of BU72 to which the pendant phenyl group is attached (Extended Data Fig. 4e-h). This geometry could be explained by a double bond between this carbon and the adjacent nitrogen. We observed a minor fraction of such a

compound by mass spectrometry in our preparation of BU72. However, this compound was not observed in mass spectrometry of the μ OR-ligand-Nb39 complex used for crystallography. Ultimately, we modeled a higher-energy conformation of BU72 within the observed electron density (see Extended Data Fig. 4 for further discussion).

In the active μ OR, there is a water-filled cavity lined by polar and aromatic side chains that extends off of the intracellular end of the ligand-binding pocket (Fig. 3e). While a similar cavity is observed in inactive μ OR, the active-state cavity is larger and completely contiguous with the morphinan-binding site. Substitution of morphinans with a cyclopropylmethyl at the tertiary amine generally results in a ligand with antagonist activity⁷. As an example, BU74, which only differs from BU72 in having a cyclopropylmethyl substituent on the tertiary amine (Fig. 3f) is an antagonist at the μ OR³³. While BU74 can be docked into the active state μ OR structure with the cyclopropylmethyl within the polar cavity, there are potential clashes with Y326^{7,43} in TM7 and W293^{6,48} in TM6. Moreover, the cyclopropylmethyl substituent would displace one or more water molecules that form part of a polar network described in more detail below. Consistent with these observations, MD simulations reveal that the antagonist BU74 is unstable in the position occupied by the agonist BU72 and rapidly shifts away from this initial pose (Extended Data Fig. 6).

Propagation of conformational changes

The structural difference in the orthosteric ligand-binding pocket between active and inactive μ OR is relatively subtle (Fig. 3b). It is difficult to identify specific interactions between the structurally rigid agonist and the receptor as being key for μ OR activation. This stands in contrast to activation of the β_2 AR and M2R, where specific polar interactions between the receptor and the smaller, more flexible agonists contribute to structural changes associated with activation. These polar interactions stabilize a 2 Å inward movement of TM5 in the β_2 AR and a 2 Å inward movement of TM6 in the M2R.

While agonist stabilized changes in the binding pocket differ for the μ OR, β_2 AR, and M2R, the overall structural changes observed at the G protein interface are very similar (Extended Data Fig. 3). The mechanism by which agonist-stabilized changes propagate to the cytoplasmic surface appears to be more similar between μ OR and the β_2 AR compared to the M2R (Fig. 4a). For both the β_2 AR and the μ OR, there is a rearrangement of the packing of a triad of conserved amino acids F^{6,44}, P^{5,50} and I^{3,40} (which we term the conserved core triad) that lie just below the binding pocket (Fig. 4a). This rearrangement is associated with a counterclockwise rotation (when viewed from the extracellular surface) and outward movement of the cytoplasmic end of TM6. Thus, the subtle agonist-stabilized rearrangement in the conserved core triad may initiate the cascade of structural changes involved in activation of the μ OR and β_2 AR. The role of the conserved core triad appears to differ in the M2R, where the smaller V111^{3,40} forms a weaker packing interaction with F396^{6,44} and P198^{5,50}. As a result, the triad in both inactive and active states of the M2R appear similar to the active states of the β_2 AR (Fig. 4a).

Given the similarity in allosteric propagation between μ OR and β_2 AR, we sought to identify how BU72 stabilizes the active conformation of the conserved core triad. In the β_2 AR, the

rearrangement of the conserved core triad can be attributed to an agonist stabilized inward movement of TM5^{12,13}. For the μ OR, however, there are no specific interactions between the receptor and BU72 that stabilize the inward movement of TM5. Instead, we identify a set of interactions that together appear to stabilize the rearrangement of the conserved core triad in the μ OR.

Both β -FNA and BU72 share a common morphinan scaffold. This common scaffold, however, is positioned differently in the inactive and active structures. In both states, residues I296^{6,51} and V300^{6,55} in TM6 and W318^{7,35} and I322^{7,39} in TM7 form a common hydrophobic surface for binding the morphinan ligands (spheres, Fig. 4b,d). While this surface is similar in both inactive and active states, differences in the position of the rigid morphinan agonist and antagonist result in differences in the positions of key ligand substituents relative to specific residues in TM3 and TM6 that are coupled to the conserved core triad of F289^{6,44}, P244^{5,50} and I155^{3,40} (Fig. 4b,d).

In the active μ OR structure, the morphinan scaffold of BU72 adopts a pose that is sterically incompatible with the inactive position of TM3. As a result, the residues of TM3 that interact with the tertiary amine (D147^{3,32}) and methyl substituent (M151^{3,36}) of the agonist shift 1.5 Å toward TM2 relative to its position in the inactive structure (Fig. 4b). We utilized MD simulations to assess whether the agonist favors this displacement in TM3. In simulations of activated μ OR with the agonist removed, the previously ligand-contacting residues on TM3 quickly relax toward their inactive positions (Fig. 4c), often without global structural change of the receptor. These motions are tightly coupled to motion of the conserved core triad residue I155^{3,40} towards its inactive position, causing it to reposition relative to F289^{6,44} (Fig. 4b,c). Notably, the position of D147^{3,32} is also coupled to the rotameric state of N150^{3,35}, which coordinates an allosteric sodium ion in the inactive state and forms a hydrogen bond with a backbone carbonyl of I146^{3,31} in the active state (Fig. 4b,c).

Another link between the ligand binding pocket and the conserved core triad may be mediated via TM6 through W293^{6,48} (Fig. 4d,e). In the active μ OR structure, the aromatic group of BU72 is positioned only slightly closer (0.6 Å) to W293^{6,48} as compared to the same aromatic group of β -FNA in the inactive state. However, MD simulations suggest that agonists stabilize W293^{6,48} in the rotamer observed in the active-state crystal structure. In simulations of the active state, removal of BU72 results in a change in the favored rotamer of W293^{6,48} (Fig. 4e). Conversely, we assessed whether an agonist bound to the inactive state would stabilize the side chain of W293^{6,48} in the rotamer associated with the active state. Here, we simulated the inactive state structure with the antagonist β -FNA replaced with the agonist β -fuoxymorphamine (β -FOA), which differs from β -FNA solely in a methyl substituent at the morphinan tertiary amine³⁴ (Extended Data Fig. 7a). In these simulations, the pose of β -FOA tends to shift towards that observed for BU72 and the TM3 residues D147^{3,32} and N150^{3,35} shift towards their active-state positions; in concert, the side chain of W293^{6,48} shifts towards its active position (Extended Data Fig. 7b,c). W293^{6,48} is spatially juxtaposed to the conserved core triad residue F289^{6,44}, and the conformation of W293^{6,48} may therefore serve as an important link between the ligand-binding pocket and the triad (Fig. 4d).

Role of polar network in GPCR activation

In addition to rearrangement of the conserved core triad, comparison of inactive and active structures of μ OR reveals an extensive network of polar interactions between the orthosteric binding pocket and the G protein-coupling interface that must rearrange upon activation (Fig. 5a). The high-resolution electron density maps of the active μ OR allow us to detect more ordered water molecules within this polar network than have been observed in other active-state GPCR structures reported to date. To provide a better comparison of this polar network, we examined the high-resolution inactive structure of the highly homologous δ OR¹¹. The inactive structure of δ OR at a resolution of 1.8 Å identifies more water molecules within this polar network than the 2.8 Å inactive structure of μ OR and therefore highlights the contribution of many hydrogen bonds in stabilizing both inactive and active states of opioid receptors (Fig. 5b). These hydrogen bonds represent many low energy molecular switches that have to be broken and reformed in a concerted manner to achieve the active conformation. The polar network interactions for inactive state μ OR are likely to be identical to the inactive state of δ OR because the specific amino acids involved in this network and their side chain conformations are identical between the two homologous receptors.

Many of the residues in the polar network are conserved (Extended Data Fig. 8a, b, e and f), suggesting that the polar network may also be conserved and play a similar role in activation of other Family A GPCRs. While there are fewer water molecules observed in the active state structure of the β_2 AR, the ones that are resolved are in the same positions as those observed in the μ OR. Even though the resolution in the active β_2 AR and M2R structures is not sufficient to observe as many ordered water molecules, the positions of the conserved side chains lining the polar core of the β_2 AR and M2R are nearly identical to those of the μ OR (Extended Data Fig. 8f), suggesting that they are stabilized by a similar hydrogen bonding network.

In the high-resolution inactive state structure of the δ OR, there is an ordered sodium ion that is adjacent to the conserved core triad and is coordinated by the side chains of D^{2.50}, N^{3.35} and S^{3.39}, as well as by W^{6.48} through a water molecule (Fig. 5b,c). A sodium ion at a similar coordination site has been observed in inactive structures of the protease activated receptor subtype 1 (PAR1)³⁵, the adenosine A_{2A} receptor (A_{2A}R)³⁶ and the β_1 adrenergic receptor (β_1 AR)³⁷. For many GPCRs, including the μ OR, agonist binding affinity and/or G protein activation is allosterically inhibited by sodium³⁸. Consistent with allosteric stabilization of the inactive state by sodium, we do not observe a sodium ion in the active state structure of the μ OR, and the residues that formed the sodium-binding site rearrange to preclude sodium binding in the active state (Fig. 5c).

The polar network ends at the cytoplasmic surface with a web of interactions involving the conserved NPxxY sequence (Fig. 5d). Upon receptor activation, the NPxxY motif in TM7 moves inward towards TM5 where N332^{7.49} and Y336^{7.53} participate in a hydrogen bond network involving Y252^{5.58} in TM5, the backbone carbonyls of L158^{3.43} in TM3 and V285^{6.40} in TM6, and three ordered water molecules (Fig. 5d). A similar hydrogen bond network was previously observed in the structure of metarhodopsin II¹⁹. Similar water-

mediated hydrogen bonds are likely present in active β_2 AR and M2R as the side chains of key residues in this region occupy similar positions (Extended Data Fig. 3b).

It is interesting to speculate on the role of this polar network in the energetics of μ OR activation. NMR studies reveal that allosteric coupling of the agonist-binding pocket and the G protein-binding interface in the μ OR is relatively weak, and structural changes in TM6 are observed only in the presence of a G protein-mimetic nanobody (Sounier *et al.*, companion manuscript). A similar observation has been made for the β_2 AR^{20-22,39}. Using both double electron-electron resonance (DEER) spectroscopy and NMR spectroscopy we observed that in the presence of a saturating concentration of the catecholamine agonist isoproterenol only 20% of β_2 AR has TM6 in an active-like conformation²⁴. This stands in contrast to the more efficient coupling between the orthosteric binding pocket and TM6 in rhodopsin, as reflected in the ability to crystallize rhodopsin in an active state without a G protein or G protein mimetic nanobody⁴⁰, and biophysical studies that reveal a stronger allosteric coupling between the orthosteric binding pocket and TM6 in rhodopsin⁴¹. Comparison of the inactive state structures of rhodopsin and the δ OR reveals that the δ OR has a more extensive polar network on the cytoplasmic side of the ligand binding pocket (Extended Data Fig. 9). This is particularly notable when considering the network of hydrogen bonds that maintain TM6 in the inactive conformation (Extended Data Fig. 9). As noted above, a similar polar network likely stabilizes the inactive states of the μ OR and β_2 AR (Extended Data Fig. 8). The less extensive polar network stabilizing the inactive state of rhodopsin is compensated for by the covalent inverse agonist, 11-*cis*-retinal. This balance of non-covalent polar interactions and a covalent ligand imparts rhodopsin with virtually no basal activity, but the ability to rapidly and efficiently respond to photoisomerization of retinal. In contrast, the polar network in the μ OR and β_2 AR help to maintain unliganded receptors in an inactive state, but the need to disrupt this network makes activation of these receptors energetically less efficient.

Conclusion

The structure of activated μ OR presented here provides a model for how efficacy is encoded within small chemical differences in otherwise structurally similar morphinan ligands. Comparison of active μ OR with other active state structures offers insights into shared and subtype-specific mechanisms for activation of Family A GPCRs. Additionally, the extensive reorganization of the polar network required to achieve the fully active state may explain the inefficient allosteric coupling of the orthosteric pocket and the G protein-coupling interface observed in NMR studies for both the μ OR and the β_2 AR. It is possible that subtle ligand-specific differences in the polar network connections may contribute to preferential activation of different signaling proteins.

Full Methods and associated references are available in the online version of the paper at www.nature.com/nature.

Online Methods

Expression and purification of μ OR

Full length *Mus musculus* μ OR bearing an amino-terminal Flag epitope tag and a carboxy-terminal 6xHis tag was expressed in *Sf9* insect cells using the BestBac baculovirus system (Expression Systems). To facilitate removal of flexible amino- and carboxy-terminal regions, a tobacco etch virus protease recognition sequence was inserted after residue 51 and a rhinovirus 3C protease recognition sequence was inserted before residue 359. Insect cells were infected with baculovirus encoding μ OR at a density of 4×10^6 cells/ml for 48-60 hours at 27° C. Receptor was solubilized and purified in a final buffer comprised of 25 mM HEPES pH 7.4, 100 mM NaCl, 0.01% MNG (Anatrace), 0.001% cholesterol hemisuccinate (CHS) as previously described⁹.

Llama immunization and selection of μ OR-binding nanobodies

Purified μ OR bound to the antagonist naloxone and with the amino- and carboxy- termini cleaved was incubated with an excess of the agonist DMT¹-DALDA (NIDA Drug Supply Program) and further purified by size exclusion chromatography in a buffer comprised of 20 mM HEPES pH 7.5, 100 mM NaCl, 0.1% dodecylmaltoside (DDM, Anatrace), 0.03% CHAPS, 0.01% CHS, and 1 μ M DMT¹-DALDA. The resulting agonist bound receptor was reconstituted into phospholipid vesicles composed of DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine, Avanti Polar Lipids) and Lipid A in a 10:1 (w:w) ratio at a final receptor concentration of 1.3 mg/ml. The resulting reconstituted receptor was flash frozen in liquid nitrogen in 100 μ g aliquots for llama immunization.

One llama was immunized over a period of 6 weeks with 0.3 mg of liposome-reconstituted μ OR purified as described above and bound to the agonist DMT¹-DALDA. A phage display library of nanobodies was prepared from peripheral blood lymphocytes as previously described⁴². μ OR-binding nanobodies were identified by selecting phage that bound liposome-reconstituted μ OR in the presence or absence of agonist. Ten clones from three families were enriched during rounds of selection. One family, which includes Nb39, bind the intracellular surface and function as G protein mimetics. Another family of nanobodies, including clone Nb35, was identified that competes directly with orthosteric antagonists of the μ OR and binds at the extracellular surface.

Expression and purification of nanobodies

Nanobodies bearing a carboxy-terminal 6xHis tag were expressed in the periplasm of *Escherichia coli* strain WK6. Cultures were grown to an OD₆₀₀ of 1.0 at 37°C in Terrific Broth medium containing 0.1% glucose, 2 mM MgCl₂, and 50 μ g/mL ampicillin and induced with 0.5 mM isopropyl- β -D-thiogalactoside (IPTG). Cells were harvested after overnight growth at 25°C and incubated in a buffer containing 200 mM Tris pH 8.0, 0.5 mM EDTA, 500 mM sucrose, 0.5 mg/mL lysozyme for 1 hour at 25°C. Bacteria were osmotically lysed by rapid dilution in a 4 \times volume of water. The periplasmic fraction was isolated by centrifugation of cell debris, and was supplemented with NaCl to a final concentration of 150 mM as well as imidazole to a final concentration of 25 mM. Nanobodies were purified from the periplasmic fraction by nickel affinity chromatography,

and were subsequently purified by size exclusion chromatography in a buffer comprised of 25 mM HEPES pH 7.5 and 100 mM NaCl. Peak fractions were pooled and concentrated to approximately 5 mM.

Radioligand characterization of BU72 and Nb39

Radioligand competition assays were performed using purified μ OR reconstituted into high-density lipoprotein (HDL) particles comprised of the lipids POPC and POPG (Avanti Polar Lipids) in a 3:2 molar ratio as previously described^{43,44}. Heterotrimeric G_i was prepared by co-expressing human $G_{i\alpha 1}$, human $G_{i\beta 1}$ and $G_{i\gamma 2}$ subunits in Hi5 insect cells using baculoviruses encoding the individual subunits. The G protein was purified as previously described²⁵.

For competition binding experiments, a mixture of 0.02 nM μ OR and 2.3 nM 3H -diprenorphine (3H -DPN, Perkin Elmer) was incubated with varying concentrations of agonist in a binding buffer comprised of 25 mM HEPES pH 7.4, 100 mM NaCl, and 0.1% BSA. Experiments were also performed with either 5 μ M Nb39 or 500 nM G_i . Binding reactions were incubated for 4 hours at 25°C. Free radioligand was separated from bound radioligand by rapid filtration onto a Whatman GF/B filter pretreated with 0.1% polyethylenimine with the aid of a 48-well harvester (Brandel). Radioligand activity was measured by liquid scintillation counting. Competition binding data were fit to a one-site model for μ OR alone and μ OR with Nb39 and a two-site model for μ OR incubated with G_i using GraphPad Prism 6.0.

Dissociation studies for BU72 were performed using the method of Motulsky and Mahan⁴⁵. 3H -DPN was diluted in an assay buffer comprised of 20 mM Tris, pH 7.4, 150 mM NaCl, and 0.05% BSA containing μ OR in HDL particles with either vehicle or different concentrations of BU72 alone or in the presence of Nb39. Binding reactions were incubated at 25°C in the dark and nonspecific binding was determined in the presence of 10 μ M naloxone. Aliquots of this binding reaction were removed at specified time points over the course of 2 or 8 hours and filtered through Whatman GF/C filters with the aid of a Brandel harvester. As above, radioligand activity was measured by liquid scintillation counting. Dissociation rates for BU72 were determined by fitting data in the 'kinetics of competitive binding' program in GraphPad Prism 6.02. For K1 and K2, rates of 3H -DPN association and dissociation were determined through independent studies following the same method as above.

Purification and crystallization of μ OR-BU72-Nb39 complex

Initial crystals of a μ OR-BU72-Nb complex diffracted to low resolution. In an effort to improve the specific activity of purified μ OR, we utilized an extracellular binding nanobody, Nb35 during the purification of the receptor. Nb35 binds in the orthosteric pocket of μ OR with a K_i of 12 nM. Purified ligand-free μ OR, with the amino- and carboxy- termini cleaved was mixed with a 2.5 \times excess of Nb35, and the complex was isolated by Ni-NTA chromatography. Functional μ OR in complex with Nb35 was eluted in a buffer containing 25 mM HEPES pH 7.5, 100 mM NaCl, 0.01% MNG, 0.001% CHS, and 250 mM imidazole. The agonist BU72 and Nb39 were then added in excess. In the presence of Nb39, BU72 has

exceptionally high affinity for the μ OR and displaces Nb35, resulting in the desired μ OR-BU72-Nb39 complex. The μ OR-BU72-Nb39 complex was isolated by size exclusion chromatography and concentrated to approximately 50 mg/mL for crystallization trials.

For crystallization, the purified μ OR-BU72-Nb39 complex was reconstituted into a 10:1 (w:w) mixture of monoolein and cholesterol (Sigma). The protein solution and lipid were mixed in a 1:1.5 ratio (w:w) and the lipidic cubic phase was attained using the two-syringe method⁴⁶. 30 nL of the resulting mesophase was dispensed onto 96-well glass plates and overlaid with 500 nL of precipitant solution using a Gryphon LCP robot (Art Robbins Instruments). Crystals grew in a precipitant comprised of 15-25% PEG300, 100 mM HEPES pH 7.0-7.5, 1% 1,2,3-heptanetriol, 0.5-1.0% Polypropylene glycol P 400 (Hampton Research) and 100-300 mM $(\text{NH}_4)_2\text{HPO}_4$. Crystals were observed after 2 days and reached full size in 1 week. Crystals were harvested with mesh grid loops (MiTeGen) and flash frozen in liquid nitrogen. Loops were screened at the Advanced Photon Source GM/CA beamlines 23ID-B and 23ID-D. Diffraction data were collected at a wavelength of 1.033 Å using a 10 μ m beam with 5 fold attenuation and exposed for 0.5-1 s. An oscillation width of 0.1-0.5 degrees was used and diffraction images from 4 crystals were merged to create the final data set.

Structure determination and refinement

Diffraction images were indexed, scaled, and merged by XDS⁴⁷ with statistics summarized in Extended Data Table 1. The structure was determined by molecular replacement in Phaser⁴⁸ with initial search models including inactive μ OR (PDB ID: 4DKL) and Nb80 (PDB ID: 3P0G). The structural model was iteratively rebuilt in Coot⁴⁹ and refined using Phenix⁵⁰. Final refinement statistics are summarized in Extended Data Table 1. Molprobit⁵¹ was used for structure analysis and indicated that 96.3% of residues were within favored Ramachandran regions with 3.7% in allowed regions. No residues were identified as Ramachandran outliers. Figures were prepared using MacPyMol (Schrödinger).

System setup for molecular dynamics simulations

Simulations of the μ opioid receptor (μ OR) were based on both the antagonist-bound inactive-state crystal structure (PDB ID: 4DKL) and the agonist-bound active-state crystal structure described in this manuscript. Coordinates were prepared by first removing all non-ligand and non-receptor molecules except for the cholesterol neighboring TM7 and for crystallographic water molecules near the receptor. For inactive μ OR simulations, the T4 lysozyme was removed and acetyl and methylamide capping groups were placed on R263^{ICL3} and E270^{ICL3}. For active μ OR simulations, the nanobody was removed. In both cases, Prime (Schrödinger, Inc.) was used to model missing side-chains, and capping groups were then added to the N- and C- termini of the receptor. Histidine residues were simulated as the neutral $\text{N}\delta$ tautomer. Other titratable residues were simulated in their dominant protonation state at pH 7 except for D114^{2,50}, which was charged in inactive simulations and neutral in active simulations. A sodium ion was placed adjacent to D114^{2,50} in inactive simulations.

The μ OR was simulated in seven distinct conditions. These include: (1) The unliganded, inactive μ OR, prepared by deleting the covalently bound, co-crystallized ligand, β -FNA, and adding a proton in its place to K233^{5,39}; (2) The inactive μ OR with the co-crystallized ligand β -FNA; (3) The inactive μ OR with agonist β -FOA (which does not bind covalently); (4) The unliganded, active μ OR, prepared by deleting the co-crystallized ligand, BU72; (5) The active μ OR with the co-crystallized ligand BU72; (6) The active μ OR with the co-crystallized ligand BU72, with the N-terminal peptide deleted; (7) The active μ OR with the antagonist BU74, with the N-terminal peptide deleted. Simulations of the active μ OR without N-terminal peptide were prepared by deleting residues 52 through 64 of the receptor. Simulations with β -FOA were prepared by docking β -FOA to the crystallographic pose of β -FNA. Simulations with BU74 were prepared by docking BU74 to the crystallographic pose of BU72 and rotating the torsion angle of the methylcyclopropyl group to agree with that of β -FNA's methylcyclopropyl group.

We performed three to six simulations per condition (Supplementary Section). Simulations in a given condition were initiated from identical structures, but with initial atom velocities assigned independently and randomly.

It should be noted that in all liganded simulations, including those with β -FNA, β -FOA, BU72, and BU74, the ligand's tertiary amine nitrogen was protonated and therefore the ligand was simulated as a cation. This is necessary for the ligand to form the conserved salt bridge with neighboring D147^{3,32}.

Each of the resulting prepared μ OR receptor structures was then aligned to the Orientations of Proteins in Membranes (OPM)⁵² entry for the inactive μ OR using MacPyMOL (Schrödinger). The μ OR was modified with disulfide bridges and inserted into a hydrated, equilibrated palmitoylcholinephosphatidylcholine (POPC) bilayer using the CHARMM-GUI interface⁵³⁻⁵⁶. Sodium and chloride ions were added to neutralize the system, reaching a final concentration of approximately 150 mM. All simulations contained one μ OR receptor embedded in a lipid bilayer with 160 POPC molecules.

Simulation protocol and analysis

Each simulation was performed on two GPUs using the CUDA version of PMEMD (Particle Mesh Ewald Molecular Dynamics) in Amber14⁵⁷⁻⁵⁹ with 2.5 fs time steps. Simulations were heated from 0 K to 100 K in the NVT ensemble and then from 100 K to 310 K in the NPT ensemble, both with 10.0 kcal mol⁻¹ Å⁻² harmonic restraints applied to the protein and to the lipids. Initial velocities were assigned randomly at the first heating step with Langevin dynamics. Subsequently, simulations were equilibrated in the NPT ensemble at 310 K (controlled with a Langevin thermostat) with pressure of 1 bar (controlled with anisotropic Berendsen weak-coupling barostat), with harmonic restraints on all protein atoms tapered off 1.0 kcal mol⁻¹ Å⁻² in a stepwise fashion every 2.0 ns starting at 5.0 kcal mol⁻¹ Å⁻² to 0.0 kcal mol⁻¹ Å⁻², for a total of 12.0 ns of equilibration. Bond lengths to hydrogen atoms were constrained using SHAKE. Production simulations were performed in the NPT ensemble at 310 K and 1 bar, using a Langevin thermostat for temperature coupling and a Monte Carlo barostat for pressure coupling, and were initiated from the final snapshot of the corresponding equilibration simulation. Nonbonded interactions were cutoff at 9.0 Å, and

long-range electrostatic interactions were computed using the particle mesh Ewald (PME) method, with an Ewald coefficient β of approximately 0.31 \AA^{-1} and B-spline interpolation of order 4. The FFT grid size was $84 \times 84 \times 96$ for all simulations. We performed a total of 27 simulations, which are summarized in the Supplementary Section.

We used the CHARMM36 parameter set for protein molecules, lipid molecules, and salt ions, and the CHARMM TIP3P model for water; protein parameters incorporated CMAP terms⁶⁰⁻⁶³. These parameters were assigned using the ParmEd implementation of Chamber, provided with AmberTools14. Ligand parameters were based on the results from the CHARMM ParamChem web server, version 0.9.7.1⁶⁴, and incorporated specific modifications to partial charges. When ParamChem reported large penalties (errors) for estimated partial charges, better estimates were determined by submitting appropriately chosen fragments to ParamChem (see below).


Parameterization of β -FNA, the co-crystallized ligand in the inactive μ OR structure, required additional steps due to the added complexity of its covalent bond with K233^{5,39} on the receptor. To assign parameters to the rest of β -FNA, the molecule was fragmented as shown in “Supplementary Section on Parameterization” and then re-assembled. In addition, a molecule consisting of K233^{5,39} bonded to the portion of β -FNA on the extracellular side of its morphinan scaffold was submitted to ParamChem, and the results were used to modify charges near the bond between the β -FNA carbon and Lys side-chain nitrogen. A modified version of the ParmEd program was used to form a bond between β -FNA and K233^{5,39}, to parameterize that and neighboring bonds, and to modify neighboring partial charges according to the derived parameters. The related ligand β -FOA (which does not bind covalently to the μ OR) was divided into the same three fragments as β -FNA for parameterization, with the following modifications: the bond between the ligand and K233^{5,39} was cleaved, a C=C double bond was formed between the two carbons adjacent to this bond, and the methylcyclopropyl group was replaced with a methyl group. The co-crystallized ligand of the active μ OR, BU72, was similarly parameterized by splitting it into fragments, individually uploading the fragments to the ParamChem web server, and assembling the results together. The fragments can be found in the Supplementary Section. The ligand, BU74, was parameterized identically to BU72, except that its tertiary amine methyl group was replaced with a methylcyclopropyl group.

Quantitative analysis of trajectories was conducted in both cpptraj, an Amber14 software package, and VMD⁶⁵. Plots were smoothed with a moving average, with a symmetric triangular smoothing window. The window length was 20 ns, except during the first 10 ns of each simulation, when the smoothing window extended from time zero to double the time at which the data was recorded. Plots were rendered in R with the ggplot2 package as well as in Python with the Matplotlib package.


To compute movement of specified atoms from the active position towards the inactive position, as plotted in Fig. 4C, the active and inactive crystal structures and each simulation frame were aligned using the C α atoms of residues 80–95, 102–13, and 181–205 (TMs 1, 2, and 4). For each specified atom, the atom position in simulation was projected onto the line connecting the atom positions in the active and inactive crystal structures, and the distance

of the projected point from the position in the active crystal structure position was determined.

Extended Data




Extended Data Figure 1. Characterization of Nb39 and lattice interactions in μOR -Nb39 crystals
a, ^3H -diprenorphine (^3H -DPN) competition binding shows increased affinity for μOR -selective agonists DAMGO and endomorphin-2 in the presence of Nb39. **b**, The dissociation half-life ($t_{1/2}$) of BU72 was determined by measuring the association rate of the antagonist ^3H -DPN in the presence of the indicated concentrations of BU72. The dissociation $t_{1/2}$ of BU72 is 43 minutes and increases to 140 minutes in presence of Nb39. Panels **a** and **b** are representative of at least three experiments performed in triplicate, and the data and error bars represent the mean \pm s.e.m. **c**, Crystal lattice packing of the μOR -Nb39 complex shows that most of the contacts are mediated by Nb39. The μOR extracellular domain is not involved in any contacts.




Extended Data Figure 2. μ OR-Nb39 interface

a, Nb39 does not penetrate as deeply into the core of the μ OR when compared with the β_2 AR-Nb80 complex and the M2R-Nb9-8 complex. In the β_2 AR-Nb80 and M2R-Nb9-8 complexes, nanobody CDR3 residues bind within the core of the receptor transmembrane bundle. In comparison, Nb39 binding involves more framework residues. Notably, seven residues of CDR3 remained unresolved in the final model of the μ OR-Nb39 complex. **b**, Nb39 interacts primarily through hydrogen bonds with residues from ICL2, ICL3 and Helix 8 of the μ OR. **c**, Schematic representation of the interactions between μ OR and Nb39 highlighting the numerous Nb39 framework interactions.




Extended Data Figure 3. Cytoplasmic domain rearrangements in conserved regions

a, The E/DRY sequence is a highly conserved motif within Family A GPCRs responsible for constraining receptors in an inactive conformation. Comparisons of inactive and active state structures around the conserved E/DRY residues at the cytoplasmic surface of the μ OR, the M2 muscarinic receptor (M2R), the β_2 adrenergic receptor (β_2 AR) and Rhodopsin (Rho) are shown here. Hydrogen bonds are shown as dotted lines. **b**, The NPxxY motif is a highly conserved sequence in TM7 among Family A GPCRs. In the active state μ OR, Y^{7.53} and N^{7.49} in TM7 interact with Y^{5.58} in TM5 and the backbone carbonyl of L^{3.43} in TM3 through a water mediated polar network. A similar network is observed in the active state of rhodopsin. While waters are not observed in the lower resolution structures of the β_2 AR and M2R, the positions of the side chains of Y^{7.53}, N^{7.49} and Y^{5.58} suggest a similar water mediated network with putative waters represented by red circles.




Extended Data Figure 4. Conformation of the binding pocket and BU72

The $2F_o - F_c$ electron density contoured at 2.0σ and within 1.8 \AA of residues comprising the active μ OR ligand-binding pocket is shown as grey mesh in **a** and **b**. The same views are shown in **c** and **d** with the omit $F_o - F_c$ density for BU72 displayed as an orange mesh. Displayed $F_o - F_c$ electron density is contoured at 3.0σ . **e**, Placement of an energetically minimized conformation of BU72 within the $F_o - F_c$ electron density shows a poor fit for the pendant phenyl ring. The conformation of BU72 was minimized using quantum mechanical Hartree-Fock methods. **f**, An alternative possible ligand structure with sp^2 geometry at the carbon adjacent to the phenyl (highlighted in red dashed circle) was initially considered due to a better fit within the electron density. This alternative ligand is predicted to be 2 daltons (Da) smaller than BU72. **g**, In order to resolve potential ambiguity in the cocrystallized ligand, we performed mass spectrometry on the same protein sample used to generate crystals of the active μ OR. The protein was precipitated in methanol and the supernatant was subjected to MALDI-MS which revealed a strong peak at $m/z = 429.226$, consistent with the expected mass of BU72. **h**, Shown is our final crystallographic model for BU72 within the $F_o - F_c$ electron density. This model likely represents a high-energy conformation of BU72. Notably, the position of the morphinan scaffold is invariant between these alternative models for the crystallized ligand.




Extended Data Figure 5. The N-terminus of the μ OR interacts with BU72

a, Surface cut-away view showing that the N-terminus forms a lid over the ligand-binding pocket. Shown in the lower panel is the ligand-binding pocket in the absence of the N-terminus. **b**, Blue mesh shows the $2F_o - F_c$ omit map contoured at 1.0σ for the N-terminus. **c**, Shown in green mesh is the $F_o - F_c$ omit map contoured at 4.0σ of an unidentified density between BU72 and H54.




Extended Data Figure 6. Molecular dynamics simulation of active μ OR bound to antagonist BU74

a, Structures of agonist BU72, and antagonists BU74 and β -funaltrexamine (β -FNA). The inactive state structure of μ OR was co-crystallized with β -FNA. **b**, BU74 was docked into the active-state structure of the μ OR based on the crystallographic pose of BU72, but in an MD simulation it rapidly moves away from this initial pose. The middle panel highlights the movements of BU74 after 560 nanoseconds (ns) of simulation and the rightmost panel shows the comparison of the BU74 pose as compared to the crystal structure of β -FNA bound to inactive μ OR. **c**, Molecular dynamics trajectory measuring the distance between the phenolic hydroxyl of Y326^{7.43} and the tertiary amine of BU74. Dotted lines show the distance between Y326^{7.43} and the same amine of BU72 in the crystal structure of active μ OR and β -FNA in the structure of inactive μ OR.




Extended Data Figure 7. Molecular dynamics simulation of inactive μ OR bound to agonist β -FOA

a, Structures of agonists BU72 and β -fuoxymorphamine (β -FOA) and antagonist β -funaltrexamine (β -FNA). **b**, MD simulation of inactive μ OR with β -FOA docked into the same pose as β -FNA in the inactive-state crystal structure of μ OR. β -FOA shifts towards TM3 with an accompanying rearrangement of TM3 residues D147^{3.32} and N150^{3.35} towards the active-state structure. The overall ligand-binding pocket resembles the active state after 455 nanoseconds (ns) of simulation. **c**, Trajectory of the W293^{6.48} Chi2 dihedral angle (indicated in the middle panel in **b**) over 700 ns of simulation. In the presence of β -FOA, the preferred rotamer for W293^{6.48} rapidly approaches a conformation similar to the one observed in the structure of active μ OR bound to BU72.



Extended Data Figure 8. Comparison of polar networks involved in GPCR activation

a, Residues involved in the polar network in the inactive state of the δ OR (PDB ID: 4N6H) and conservation of those residues in β_2 AR, M2R, and rhodopsin. **b**, Residues involved in the polar network in active state μ OR and conservation in β_2 AR, M2R, and rhodopsin. **c**, Water-mediated polar network in the inactive structure of the δ OR involves residues from TM1, TM2, TM3, TM5, TM6 and TM7. **d**, An identical view as in (c) of the polar network in the active μ OR. **e**, Residues involved in the polar network in inactive structures of δ OR, β_2 AR and M2R are conserved both in sequence and conformation. **f**, In active μ OR, β_2 AR and M2R, the residues within the polar network are again conserved in sequence and conformation.



Extended Data Figure 9. Differences in TM6 polar network in opioid receptors and rhodopsin
a, The entire set of contacts within the polar network that include a residue within TM6 is displayed for the inactive δ OR, active μ OR, and inactive and active rhodopsin (Rho). **b**, Helix wheel representation of TM6 showing polar contacts. Notably, the inactive δ OR engages in many more polar contacts with neighboring residues as compared to inactive rhodopsin. Additionally, the active states of both μ OR and rhodopsin have fewer polar contacts than the inactive state.

Extended Data Table 1
Data collection and refinement statistics (molecular replacement)

	μ OR-BU72-Nb39 ^a
Data collection^b	
Space group	$I2_12_12_1$
Cell dimensions	
a, b, c (Å)	44.4, 144.0, 209.9
α, β, γ (°)	90.0, 90.0, 90.0
Resolution (Å)	50.0-2.07 (2.12-2.07)
R_{merge} (%)	11.2 (153.6)
$\langle I/\sigma I \rangle$	11.0(1.7)
$CC_{1/2}$ (%)	99.2 (64.7)
Completeness (%)	99.8 (100.0)
Redundancy	8.6 (8.8)

μOR-BU72-Nb39^a	
Refinement	
Resolution (Å)	42.5-2.1 (2.15-2.10)
Number of reflections	39,948
$R_{\text{work}}/R_{\text{free}}$ (%)	18.53/22.15 (25.83/28.71)
Number of atoms	
Protein	3,278
Ligand (BU72)	32
Lipid, water and others	208
B-factors (Å ²)	
Protein	56.89
Ligand (BU72)	39.50
Lipid, water and others	69.91
R.M.S. deviation from ideality	
Bond lengths (Å)	0.008
Bond angles (°)	1.193
Ramachandran statistics ^c (%)	
Favored	96.1
Allowed	3.9
Outliers	0

^aDiffraction data from 4 crystals were merged into a complete data set

^bHighest resolution shell statistics are shown in parentheses

^cAs calculated by Molprobit

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We acknowledge support from the Stanford Medical Scientist Training Program and the American Heart Association (A.M.), National Institutes of Health grants R37DA036246 (B.K.K. and S.G.) and R01GM083118 (B.K.K.), a Terman Faculty Fellowship (R.O.D.), Eli Lilly and Company through the Lilly Research Program (R.O.D.), and the Mathers Foundation (B.K.K. and W.I.W). We also acknowledge the National Institute of Drug Abuse Drug Supply Program for providing DMT¹-DALDA. We thank Damien Maurel and Sandra Agnel from the ARPEGE facility (Institut de Génomique Fonctionnelle) for assistance with cell-based G_i coupling assays, Hassan El Hassan for expert technical assistance, and Samuel Hertig, Naomi Latorraca, and Kilian Cavalotti for assistance with MD simulations and analysis.

References

- Matthes HW, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ -opioid-receptor gene. 1996
- Brownstein MJ. A brief history of opiates, opioid peptides, and opioid receptors. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90:5391–5393. [PubMed: 8390660]
- Schumacher, MA.; Basbaum, AI.; Naidu, RK. Basic & Clinical Pharmacology, 13e. Katzung, Bertram G.; Trevor, Anthony J., editors. McGraw-Hill Medical; 2015.

4. Raehal KM, Walker JK, Bohn LM. Morphine side effects in β -arrestin 2 knockout mice. *Journal of Pharmacology and Experimental Therapeutics*. 2005; 314:1195–1201. [PubMed: 15917400]
5. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG. $[\mu]$ -Opioid receptor desensitization by $[\beta]$ -arrestin-2 determines morphine tolerance but not dependence. *Nature*. 2000; 408:720–723. [PubMed: 11130073]
6. Bohn LM, et al. Enhanced Morphine Analgesia in Mice Lacking β -Arrestin 2. *Science*. 1999; 286:2495–2498.10.1126/science.286.5449.2495 [PubMed: 10617462]
7. Pasternak GW, Pan YX. μ Opioids and Their Receptors: Evolution of a Concept. *Pharmacological Reviews*. 2013; 65:1257–1317.10.1124/pr.112.007138 [PubMed: 24076545]
8. Chavkin C, Goldstein A. Specific receptor for the opioid peptide dynorphin: structure--activity relationships. *Proceedings of the National Academy of Sciences*. 1981; 78:6543–6547.
9. Manglik A, et al. Crystal structure of the $[\mu]$ -opioid receptor bound to a morphinan antagonist. *Nature*. 2012; 485:321–326. doi: <http://www.nature.com/nature/journal/v485/n7398/abs/nature10954.html> - supplementary-information. [PubMed: 22437502]
10. Granier S, et al. Structure of the δ -opioid receptor bound to naltrindole. *Nature*. 2012; 485:400–404. doi: <http://www.nature.com/nature/journal/v485/n7398/abs/nature11111.html> - supplementary-information. [PubMed: 22596164]
11. Fenalti G, et al. Molecular control of $[\text{dgr}]$ -opioid receptor signalling. *Nature*. 2014; 506:191–196. <http://www.nature.com/nature/journal/v506/n7487/abs/nature12944.html> - supplementary-information. 10.1038/nature12944 [PubMed: 24413399]
12. Rasmussen SGF, et al. Structure of a nanobody-stabilized active state of the $[\text{bgr}]2$ adrenoceptor. *Nature*. 2011; 469:175–180. doi:<http://www.nature.com/nature/journal/v469/n7329/abs/nature09648.html> - supplementary-information. [PubMed: 21228869]
13. Ring AM, et al. Adrenaline-activated structure of $[\text{bgr}]2$ -adrenoceptor stabilized by an engineered nanobody. *Nature*. 2013; 502:575–579. <http://www.nature.com/nature/journal/v502/n7472/abs/nature12572.html> - supplementary-information. 10.1038/nature12572 [PubMed: 24056936]
14. Cherezov V, et al. High-Resolution Crystal Structure of an Engineered Human $\beta 2$ -Adrenergic G Protein–Coupled Receptor. *Science*. 2007; 318:1258–1265.10.1126/science.1150577 [PubMed: 17962520]
15. Rosenbaum DM, et al. GPCR Engineering Yields High-Resolution Structural Insights into $\beta 2$ -Adrenergic Receptor Function. *Science*. 2007; 318:1266–1273.10.1126/science.1150609 [PubMed: 17962519]
16. Haga K, et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. *Nature*. 2012; 482:547–551. doi: <http://www.nature.com/nature/journal/v482/n7386/abs/nature10753.html> - supplementary-information. [PubMed: 22278061]
17. Kruse AC, et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. *Nature*. 2013; 504:101–106. <http://www.nature.com/nature/journal/v504/n7478/abs/nature12735.html> - supplementary-information. 10.1038/nature12735 [PubMed: 24256733]
18. Palczewski K, et al. Crystal Structure of Rhodopsin: A G Protein–Coupled Receptor. *Science*. 2000; 289:739–745.10.1126/science.289.5480.739 [PubMed: 10926528]
19. Choe HW, et al. Crystal structure of metarhodopsin II. *Nature*. 2011; 471:651–655. doi: <http://www.nature.com/nature/journal/v471/n7340/abs/10.1038-nature09789-unlocked.html> - supplementary-information. [PubMed: 21389988]
20. Rosenbaum DM, et al. Structure and function of an irreversible agonist- $[\text{bgr}]2$ adrenoceptor complex. *Nature*. 2011; 469:236–240. doi: <http://www.nature.com/nature/journal/v469/n7329/abs/nature09665.html> - supplementary-information. [PubMed: 21228876]
21. Nygaard R, et al. The Dynamic Process of $\beta 2$ -Adrenergic Receptor Activation. *Cell*. 2013; 152:532–542. doi: <http://dx.doi.org/10.1016/j.cell.2013.01.008>. [PubMed: 23374348]
22. Manglik A, Kobilka B. The role of protein dynamics in GPCR function: insights from the $\beta 2\text{AR}$ and rhodopsin. *Current opinion in cell biology*. 2014; 27:136–143.10.1016/j.ceb.2014.01.008 [PubMed: 24534489]
23. Manglik A, et al. Structural Insights into the Dynamic Process of $\beta 2$ -Adrenergic Receptor Signaling. *Cell*. 2015; 161:1101–1111.10.1016/j.cell.2015.04.043 [PubMed: 25981665]

24. De Lean A, Stadel JM, Lefkowitz RJ. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. *Journal of Biological Chemistry*. 1980; 255:7108–7117. [PubMed: 6248546]
25. Rasmussen SGF, et al. Crystal structure of the [bgr]2 adrenergic receptor-Gs protein complex. *Nature*. 2011; 477:549–555. doi: <http://www.nature.com/nature/journal/v477/n7366/abs/nature10361.html> - supplementary-information. [PubMed: 21772288]
26. Schiller PW, et al. Synthesis and in vitro opioid activity profiles of DALDA analogues. *European Journal of Medicinal Chemistry*. 2000; 35:895–901. doi: [http://dx.doi.org/10.1016/S0223-5234\(00\)01171-5](http://dx.doi.org/10.1016/S0223-5234(00)01171-5). [PubMed: 11121615]
27. Neilan CL, et al. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist. *European Journal of Pharmacology*. 2004; 499:107–116. doi: <http://dx.doi.org/10.1016/j.ejphar.2004.07.097>. [PubMed: 15363957]
28. Caffrey M. Crystallizing Membrane Proteins for Structure Determination: Use of Lipidic Mesophases. *Annual Review of Biophysics*. 2009; 38:29–51.10.1146/annurev.biophys.050708.133655
29. Ballesteros JA, Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. *Methods in Neurosciences*. 1995; 25:366–428.10.1016/S1043-9471(05)80049-7
30. Wu H, et al. Structure of the human [kgr]-opioid receptor in complex with JDTic. *Nature*. 2012; 485:327–332. doi: <http://www.nature.com/nature/journal/v485/n7398/abs/nature10939.html> - supplementary-information. [PubMed: 22437504]
31. Chaturvedi K, Shahrestanifar M, Howells RD. μ Opioid receptor: role for the amino terminus as a determinant of ligand binding affinity. *Molecular Brain Research*. 2000; 76:64–72. doi: [http://dx.doi.org/10.1016/S0169-328X\(99\)00332-0](http://dx.doi.org/10.1016/S0169-328X(99)00332-0). [PubMed: 10719216]
32. Gales C, et al. Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. *Nature structural & molecular biology*. 2006;13, 778–786.10.1038/nsmb1134
33. Husbands SM, et al. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism. *European Journal of Pharmacology*. 2005; 509:117–125. doi: <http://dx.doi.org/10.1016/j.ejphar.2004.12.035>. [PubMed: 15733546]
34. Takemori AE, Larson DL, Portoghese PS. The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone. *Eur J Pharmacol*. 1981; 70:445–451. [PubMed: 6263637]
35. Zhang C, et al. High-resolution crystal structure of human protease-activated receptor 1. *Nature*. 2012; 492:387–392. doi: <http://www.nature.com/nature/journal/v492/n7429/abs/nature11701.html> - supplementary-information. [PubMed: 23222541]
36. Liu W, et al. Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions. *Science*. 2012; 337:232–236.10.1126/science.1219218 [PubMed: 22798613]
37. Miller-Gallacher JL, et al. The 2.1 Å Resolution Structure of Cyanopindolol-Bound β ₁-Adrenoceptor Identifies an Intramembrane Na⁺ Ion that Stabilises the Ligand-Free Receptor. *PLoS ONE*. 2014; 9:e92727.10.1371/journal.pone.0092727 [PubMed: 24663151]
38. Pert CB, Pasternak G, Snyder SH. Opiate agonists and antagonists discriminated by receptor binding in brain. *Science*. 1973; 182:1359–1361. [PubMed: 4128222]
39. Manglik A, et al. Structural insights into the dynamic process of beta2-adrenergic receptor signaling. *Cell*. 2015
40. Park JH, Scheerer P, Hofmann KP, Choe HW, Ernst OP. Crystal structure of the ligand-free G-protein-coupled receptor opsin. *Nature*. 2008; 454:183–187. [PubMed: 18563085]
41. Knierim B, Hofmann KP, Gartner W, Hubbell WL, Ernst OP. Rhodopsin and 9-demethyl-retinal analog: effect of a partial agonist on displacement of transmembrane helix 6 in class A G protein-coupled receptors. *The Journal of biological chemistry*. 2008; 283:4967–4974.10.1074/jbc.M703059200 [PubMed: 18063586]
42. Pardon E, et al. A general protocol for the generation of Nanobodies for structural biology. *Nat Protocols*. 2014; 9:674–693. <http://www.nature.com/nprot/journal/v9/n3/abs/nprot.2014.039.html> - supplementary-information. 10.1038/nprot.2014.039 [PubMed: 24577359]

43. Whorton MR, et al. A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. *Proceedings of the National Academy of Sciences of the United States of America*. 2007; 104:7682–7687.10.1073/pnas.0611448104 [PubMed: 17452637]
44. Kuszak AJ, et al. Purification and functional reconstitution of monomeric mu-opioid receptors: allosteric modulation of agonist binding by Gi2. *The Journal of biological chemistry*. 2009; 284:26732–26741.10.1074/jbc.M109.026922 [PubMed: 19542234]
45. Motulsky HJ, Mahan LC. The kinetics of competitive radioligand binding predicted by the law of mass action. *Molecular pharmacology*. 1984; 25:1–9. [PubMed: 6708928]
46. Caffrey M, Cherezov V. Crystallizing membrane proteins using lipidic mesophases. *Nat Protocols*. 2009; 4:706–731. [PubMed: 19390528]
47. Kabsch W. XDS. *Acta Crystallographica Section D*. 2010; 66:125–132.10.1107/S0907444909047337
48. McCoy AJ, et al. Phaser crystallographic software. *Journal of Applied Crystallography*. 2007; 40:658–674.10.1107/S0021889807021206 [PubMed: 19461840]
49. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. *Acta Crystallographica Section D*. 2004; 60:2126–2132.10.1107/S0907444904019158
50. Afonine PV, et al. Towards automated crystallographic structure refinement with phenix.refine. *Acta Crystallographica Section D*. 2012; 68:352–367.10.1107/S0907444912001308
51. Chen VB, et al. MolProbity: all-atom structure validation for macromolecular crystallography. *Acta crystallographica Section D, Biological crystallography*. 2010; 66:12–21.10.1107/S0907444909042073
52. Lomize MA, Lomize AL, Pogozheva ID, Mosberg HI. OPM: Orientations of Proteins in Membranes database. *Bioinformatics*. 2006; 22:623–625.10.1093/bioinformatics/btk023 [PubMed: 16397007]
53. Brooks BR, et al. CHARMM: The biomolecular simulation program. *Journal of Computational Chemistry*. 2009; 30:1545–1614.10.1002/jcc.21287 [PubMed: 19444816]
54. Jo S, Kim T, Im W. Automated Builder and Database of Protein/Membrane Complexes for Molecular Dynamics Simulations. *PLoS ONE*. 2007; 2:e880. [PubMed: 17849009]
55. Jo S, Kim T, Iyer VG, Im W. CHARMM-GUI: A web-based graphical user interface for CHARMM. *Journal of Computational Chemistry*. 2008; 29:1859–1865.10.1002/jcc.20945 [PubMed: 18351591]
56. Wu EL, et al. CHARMM-GUI Membrane Builder toward realistic biological membrane simulations. *Journal of Computational Chemistry*. 2014; 35:1997–2004.10.1002/jcc.23702 [PubMed: 25130509]
57. Case DA, et al. Amber 14. 2014
58. Le Grand S, Götz AW, Walker RC. SPFP: Speed without compromise—A mixed precision model for GPU accelerated molecular dynamics simulations. *Computer Physics Communications*. 2013; 184:374–380.
59. Salomon-Ferrer R, Götz AW, Poole D, Le Grand S, Walker RC. Routine microsecond molecular dynamics simulations with Amber on GPUs. 2. Explicit solvent particle mesh Ewald. *Journal of Chemical Theory and Computation*. 2013; 9:3878–3888. [PubMed: 26592383]
60. Best RB, et al. Optimization of the Additive CHARMM All-Atom Protein Force Field Targeting Improved Sampling of the Backbone ϕ , ψ and Side-Chain χ_1 and χ_2 Dihedral Angles. *Journal of Chemical Theory and Computation*. 2012; 8:3257–3273.10.1021/ct300400x [PubMed: 23341755]
61. Klauda JB, et al. Update of the CHARMM All-Atom Additive Force Field for Lipids: Validation on Six Lipid Types. *The Journal of Physical Chemistry B*. 2010; 114:7830–7843.10.1021/jp101759q [PubMed: 20496934]
62. MacKerell AD, et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. *The Journal of Physical Chemistry B*. 1998; 102:3586–3616. [PubMed: 24889800]
63. MacKerell AD, Feig M, Brooks CL. Extending the treatment of backbone energetics in protein force fields: Limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. *Journal of computational chemistry*. 2004; 25:1400–1415. [PubMed: 15185334]

64. Vanommeslaeghe K, et al. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. *Journal of Computational Chemistry*. 2010; 31:671–690.10.1002/jcc.21367 [PubMed: 19575467]
65. Humphrey W, Dalke A, Schulten K. VMD: Visual molecular dynamics. *Journal of Molecular Graphics*. 1996; 14:33–38. doi: [http://dx.doi.org/10.1016/0263-7855\(96\)00018-5](http://dx.doi.org/10.1016/0263-7855(96)00018-5). [PubMed: 8744570]




Figure 1. Activated structure of μ OR bound to BU72 and Nb39

a, Structures of prototypical opioid ligands highlighting regions involved in encoding efficacy (message) and selectivity (address). **b**, ^3H -diprenorphine (^3H -DPN) radioligand competition binding of μ OR in HDL particles. In the presence of G_i , the affinity of the morphinan agonist BU72 increases 47 fold. The two observed binding sites indicate the affinity of BU72 for receptor coupled to G_i and uncoupled to G_i . A similar 29-fold increase in affinity is observed in presence of Nb39. The binding curves are representative of at least three experiments performed in triplicate, and the data and error bars represent the mean \pm s.e.m. **c**, Structure of the high affinity agonist BU72. **d**, Overall structure of the μ OR-BU72-Nb39 complex. **e**, An interface between TM1-TM2 and H8 is observed in both inactive and active structures of the μ OR. The residues comprising the interface are highlighted in dark colors on the surface view. **f**, The TM5-TM6 interface observed for inactive μ OR is not compatible with the active state due to clashing residues in TM5 and TM6 (highlighted in red).




Figure 2. Structural comparison of inactive and active μ OR

a, Active μ OR undergoes a 10 Å outward displacement of TM6 on activation. The extracellular domain of the receptor shows minimal changes upon activation. **b**, Comparison of the conserved E/DRY motif in the inactive structures of μ OR (blue) and rhodopsin (Rho, brown) shows a polar interaction between R3.50 and T6.34 in μ OR, analogous to the ionic lock between R3.50 and E6.30 observed for rhodopsin. **c**, Comparison of the same region in the active state of μ OR (green) and Rho (purple) shows a conserved interaction between R3.50 and Y5.58.




Figure 3. μ OR agonist binding pocket

a, BU72 and β -funaltrexamine (β -FNA) occupy a similar pose in the μ OR binding pocket. The common morphinan scaffold shared by both ligands is highlighted. **b**, Binding pocket residues of inactive (blue) and active (green) μ OR viewed from the extracellular side. **c**, Polar interactions between BU72 and active μ OR. **d**, BU72 and binding pocket residues shown with the proximal amino-terminus (grey). **e**, View of the polar cavity extending towards the intracellular side of μ OR in the active state. **f**, The cyclopropylmethyl group of the antagonist BU74 can be docked to fit within the polar cavity of the active state. However, MD simulations show that this pose is unstable (Extended Data Figure 6).




Figure 4. Mechanisms of allosteric coupling in μ OR

a, Comparison of the structural rearrangements in the conserved core triad of μ OR, β_2 AR, and M2R. **b**, The morphinan ligands BU72 and β -FNA bind to the μ OR with a shared hydrophobic surface shown in spheres. BU72 binding results in a 1.5 Å displacement of TM3 towards TM2 and a rotameric change in the sodium coordinating residue N150^{3,35}. Red arrows highlight displacement of the ligand or TM3 upon activation. **c**, In an MD simulation initiated from the active μ OR structure but with the agonist BU72 removed from the binding site, residues in TM3, including the conserved core triad residue I155^{3,40}, adopt an inactive-like conformation. The motions of I155^{3,40} and ligand-contacting residue D147^{3,32} are tightly coupled throughout the simulation. Atom positions during simulation are plotted relative to the active structure, with positive values representing displacement toward the position in the inactive structure (see Full Methods). Dashed horizontal lines represent the positions of the indicated atoms in the inactive structure. **d**, W293^{6,48} is slightly closer to the phenolic aromatic of the morphinan in the active state of μ OR. **e**, MD simulations show that removal of the agonist BU72 from the active structure results in a change in the preferred rotamer of W293^{6,48}. MD results were consistent across multiple simulations; see Supplementary Section.




Figure 5. Rearrangement of a conserved polar network

a, b Comparison of the water-mediated polar network in the active μ OR and high-resolution inactive δ OR (PDB ID: 4N6H). To simplify comparisons between different receptors, only Ballesteros-Weinstein numbers are used to label amino acid side chains. The network extends from the orthosteric ligand-binding site to the G protein-coupling domain of the receptor. **c**, The active structure of μ OR reveals the basis for sodium ion allosteric regulation of GPCR function. Rearrangement of S3.39 and N3.35 eliminates the sodium ion coordination site in the active state. **d**, Conserved hydrogen bonding network in the NPxxY region between active μ OR and rhodopsin.